Project programme
|
|
|
|
EFA projects
|
606.742,00 |
|
|
| |
Atopic Eczema Consensus AbbVie |
30.000,00 |
4,94% |
2,75% |
| |
Atopic Eczema Consensus Sanofi/Regeneron |
115.000,00 |
18,95% |
10,55% |
| |
Breathe Chiesi |
40.000,00 |
6,59% |
3,67% |
| |
Breathe Astra Zeneca |
66.200,00 |
10,91% |
6,07% |
| |
Breathe Roche |
30.000,00 |
4,94% |
2,75% |
| |
Breathe Deferred income from 2022 |
90.000,00 |
14,83% |
8,25% |
| |
GUIDE Asthma deferred income from 2022 |
40.570,00 |
6,69% |
3,72% |
| |
Interest Group Sanofi/Regeneron |
40.000,00 |
6,59% |
3,67% |
| |
COPD Standards of Care Roche |
35.000,00 |
5,77% |
3,21% |
| |
COPD Standards of Care Sanofi/Regeneron |
60.000,00 |
9,89% |
5,50% |
| |
Capacity Building Astra Zeneca |
51.572,00 |
8,50% |
4,73% |
| |
Capacity Building Deferred income from 2022 |
8.400,00 |
1,38% |
0,77% |
| |
Deferred income 2023 to EFA Projects 2024 |
-171.200,00 |
|
|
EU projects
|
100.796,43 |
|
|
| |
3TR |
5.443,63 |
5,40% |
0,50% |
| |
ImmUniverse |
9.995,18 |
9,92% |
0,92% |
| |
TOLIFE |
18.556,86 |
18,41% |
1,70% |
| |
SynAir-G |
52.417,00 |
52,00% |
4,81% |
| |
CURE |
14.383,76 |
14,27% |
1,32% |